AVITA Medical to Announce Second Quarter 2023 Financial Results
July 20 2023 - 4:05PM
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative
medicine company leading the development and commercialization of
first-in-class devices and autologous cellular therapies for skin
restoration, announced today that it will report its second quarter
2023 financial results after the close of the U.S. financial
markets on Thursday, August 10, 2023. AVITA Medical will host a
conference call and webcast that day at 1:30 p.m. Pacific Time to
discuss its financial results and recent business highlights.
To access the live call via telephone, please register in
advance using the link here. Upon registering, each participant
will receive an email confirmation with dial-in numbers and a
unique personal PIN that can be used to join the call.
The live webcast of the call may be accessed by visiting the
Investor Relations section of the AVITA Medical website at
https://ir.avitamedical.com/events-and-presentations. A replay of
the webcast will be available shortly after the conclusion of the
call.
ABOUT AVITA MEDICAL, INC.AVITA Medical® is a
regenerative medicine company leading the development and
commercialization of devices and autologous cellular therapies for
skin restoration. The RECELL® System technology platform, approved
by the FDA for the treatment of thermal burn wounds and
full-thickness skin defects and for repigmentation of stable
depigmented vitiligo lesions, harnesses the regenerative properties
of a patient’s own skin to create Spray-On Skin™ cells. Delivered
at the point-of-care, RECELL enables improved clinical outcomes.
RECELL is the catalyst of a new treatment paradigm and AVITA
Medical is leveraging its proven and differentiated capabilities to
develop first-in-class cellular therapies for multiple
indications.
In international markets, our products are approved under the
RECELL System brand to promote skin healing in a wide range of
applications including burns, soft tissue repair, vitiligo, and
aesthetics. The RECELL System is TGA-registered in Australia,
received CE-mark approval in Europe and has PMDA approval in
Japan.
To learn more, visit www.avitamedical.com.
FOR FURTHER INFORMATION:
Investors & MediaAVITA Medical,
Inc.Jessica EkebergPhone +1-661-904-9269
investor@avitamedical.commedia@avitamedical.com |
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Sep 2023 to Sep 2024